30 October 2025

Presentation on FY25 Q1 Results

Bioxyne Limited (ASX: BXN) (Bioxyne or Company) is pleased to attach a presentation on the first quarter results for FY2025.

For video transcript please see: https://youtu.be/s8gNrn3E7as

This presentation approved for release to the ASX by The Board.

About Bioxyne Limited:

Bioxyne Limited is an Australian pharmaceutical company focused on the development and commercialization of innovative medicines and active pharmaceutical ingredients.

For further information, please contact:

Bioxyne Limited
Investor Relations
Email: info@bioxyne.com
Phone: +61 2 9078 8180
Website: www.bioxyne.com

About Bioxyne

Bioxyne Limited (ASX:BXN) is an Australian-headquartered international consumer health and pharmaceutical company (incorporated in 2000) with a focus on clinically effective health and wellness products, psychotropic and investigational medicines.

About Breathe Life Sciences (BLS)

Breathe Life Sciences ("BLS") is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and GMP-licensed manufacturer, wholesaler, importer and exporter of controlled substances (S3, S4, S8, S9), including medicinal cannabis, Psilocybin, and MDMA.

BLS was founded in 2018 and has quickly expanded into a multi-national business focused on alternative therapeutics and investigational medicines. The company's corporate head office is in Sydney, with operations and licensed manufacturing, warehousing, import/export, sales and distribution centres in Queensland (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

The BLS business model is focused on manufacturing final dose form medicines, sales and distribution. BLS sources raw materials and API from suppliers in 5 continents and is the Australian market leading manufacturer of therapeutic goods including cannabis, MDMA, and Psilocybin.

Outside of Australia the BLS Group operates in pharmaceuticals, medical cannabis, consumer health products, and novel foods (CBD). In the UK, Europe and Japan, the Company engages in the following activities:

a) Owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand. Internationally recognized for its cannabis-based food supplements, lifestyle products, functional mushrooms and nootropics, and prescription medicines in Australia.

b) Contract manufacture and wholesale of raw materials and cannabinoid extracts in Japan, UK and Europe.

c) Contract / white label manufacture of consumer health products for brands in Japan, UK and Europe in company-owned facilities.

d) Research and development of novel medicines.

e) Direct sales via online and wholesale of BLS-owned consumer brands, such as Dr Watson®

- **United Kingdom:** drwatsoncbd.com
- **UK / EU:** breathelifesciences.com

f) Export and supply of medicinal cannabis products and manufacturing services to UK and European markets.

Corporate: bioxyne.com
Australia: bls.com.au
International: breathelifesciences.com







PHARMACEUTICAL GRADE

DISCLAIMER

This presentation (Presentation) has been prepared by Bioxyne Limited ABN 97 084 464 193 (Bioxyne or the Company).

The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. The information in this presentation is subject to change without notice and, subject only to any legal obligations to do so, Bioxyne does not have any obligation to correct or update the contents of this Presentation.

The Presentation contains certain "forward-looking statements". The words "forecast", "expect", "anticipate", "estimate", "intend", "believe", "guidance", "should", "could", "may", "will", "predict", "plan" and other similar expressions are intended to identify forward-looking statements. Indications of, and guidance on, future earnings and financial position and performance are also forward-looking statements. Forward-looking statements, opinions and estimates provided in this Presentation are based on assumptions and contingencies which are subject to change without notice and involve known and unknown risks and certainties and other factors which are beyond the control of Bioxyne, and its directors and management, and may involve significant elements of subjective judgement and assumptions as to future events which may or may not be correct. This includes statements about market and industry trends, which are based on interpretations of current market conditions.

Forward-looking statements are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. Actual results, performance or achievements may differ materially from those expressed or implied in such statements and any projections and assumptions on which these statements are based. Recipients are cautioned not to place undue reliance on forward-looking statements. Refer to the risk factors section of this Presentation for some of the key known risks. No representation or warranty, express or implied, is made as to the accuracy, likelihood of achievement or reasonableness of any forecasts, prospects, returns or statements in relation to future matters contained in this Presentation.

The forward-looking statements are based on information available to Bioxyne as at the date of this Presentation. Circumstances may change and the contents of this Presentation may become outdated as a result. Except as required by law or regulation, none of Bioxyne, its representatives or advisers undertakes any obligation to provide any additional or updated information whether as a result of a change in expectations or assumptions, new information, future events or results or otherwise. Indications of, and guidance or outlook on, future earnings or financial position or performance are also forward-looking statements.

No party other than Bioxyne has authorised or caused the issue, lodgement, submission, dispatch or provision at the end of this Presentation, or takes any responsibility for, or makes or purports to make any statements, representations or undertakings in this Presentation. To the maximum extent permitted by law, Bioxyne (including its subsidiaries, related bodies corporate, shareholders, affiliates, advisers and agents):

- disclaims all responsibility and liability (including, without limitation, any liability arising from fault, negligence or negligent misstatement) for any loss arising from this Presentation or reliance on anything contained in or omitted from it or otherwise arising in connection with this Presentation;
- disclaims any obligations or undertaking to release any updates or revision to the information in this Presentation to reflect any change in expectations or assumptions; and
- does not make any representation or warranty, express or implied, as to the accuracy, reliability or completeness of the information in this Presentation or the likelihood of fulfilment of any forward-looking statement or any event or results expressed or implied in any forward-looking statement.

Not An Offer

This Presentation is not a prospectus, product disclosure document or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This Presentation is for information purposes only and should not be considered as, an offer, solicitation, inducement, recommendation or an invitation to acquire securities in Bioxyne or any other financial products, and neither this document nor any of its contents will form the basis of any contract or commitment.

This Presentation may not be distributed to any person in any country outside Australia except to the extent permitted under applicable laws. The release, publication or distribution of this Presentation (including an electronic copy) outside Australia may be restricted by law. If you come into possession of this Presentation, you should observe such restrictions and should seek your own advice on such restrictions. Any non-compliance with these restrictions may contravene applicable securities laws.

Not Financial Product Advice

This Presentation is not financial product, investment advice or a recommendation to acquire Bioxyne securities and has been prepared without taking into account the objectives, financial situation or needs of individuals. Each recipient of this Presentation should make its own enquiries and investigations regarding all information in this Presentation including, but not limited to, the assumptions, uncertainty and contingencies which may affect future operations of Bioxyne and the impact that different future outcomes may have on Bioxyne. Before making an investment decision prospective investors should consider the appropriateness of the information having regard to their own objectives, financial situation and needs, and seek legal, taxation and financial advice appropriate to their jurisdiction and circumstances. Bioxyne is not licensed to provide financial product advice in respect of its securities or any other financial products.

Q1 FY26 OVERVIEW

Q1 FY26 OVERVIEW

The Board reconfirms its guidance of $65m to $75m Revenue for FY26 and $11.5m to $13.5m Underlying EBITDA, underpinned by strong Q1 results

- Record quarterly revenue of $14.1 million, representing a 210% increase on Q1 FY25 and a 47% increase on Q4 FY25
- Substantial investment in Cannabis Flower procurement and working capital to meet European demand
- Purchase orders from Germany A$5.1m (A$2.2m invoiced in Q1, with the balance to be invoiced in Q2) for the quarter with forecasted re-orders in early CY26
- Completed dual listing on Frankfurt Stock Exchange, ticker PR8.F
- Planning for UK manufacturing operations and EU operating facilities well advanced
- Positive regulatory developments in Germany and United States
- Cash on hand of $4.5 million (excluding $1.1m R&D refund from FY24 to be received in Q2) at Quarter end
- Record quarterly Cash Receipts of $12.9m generated a material increase on both the prior corresponding period and the previous quarter

REVENUE GROWTH

Record quarterly revenue of $14 million, representing a 210% increase on Q1 FY25 and a 47% increase on Q4 FY25

- $14.1 million revenue attributable to significant performance by BLS Australia with key growth areas being white label cannabis flower, vapes, pastilles, and oils manufacturing.
- Further investment in additional clean rooms will increase manufacturing capacity for supply to local and international markets from Australia.
- Germany delivered its first major sale during the quarter in the amount of A$2.2 million.
- The Company has advanced its discussions with regulators in the UK and EU to accelerate set up of local manufacturing and distribution facilities in these key markets.
- **Internal management accounts are inline with the required run-rate to meet or exceed stated guidance of $11.5m to $13.5m Underlying EBITDA in FY26.**



CASH FLOW

The Company invested an additional $2.5m in inventory and $1.5m in net working capital to meet growing demand

- The Company generated cash receipts figure of $12.95m during the quarter, representing a material increase on both the prior corresponding period of Q4 FY24 and the previous quarter.
- Cash from operations was an outflow of $4.1m in Q1 FY26 with further investment in inventory $2.5m and net working capital of $1.5m to meet the growing trajectory of the business and deliver FY26 guidance.
- The Company made material investments in Cannabis Flower during the quarter pushing inventory on hand to ~A$6.1m (up from $3.6m in Q4 FY25).
- Company planned and budgeted the operating cash outflow of $4.1m and capital expenditure of $0.25m in the quarter as a part of its plans for significant year over year growth.



OUTLOOK

Substantial growth anticipated in FY26 with multiple growth drivers underpinning revenue & margin expansion

EUROPE

Continue to accelerate controlled drugs and GMP manufacturing accreditation in Czechia to serve EU markets

UK

Continue to progress controlled drugs and GMP manufacturing accreditation in the UK. Working with local government to secure grant funding and tax breaks

AUS

Invest in inventory to meet significant international and Australian demand and to continue driving sales growth

Improving processes, including ERP systems, to manage the growing business in Australia, UK and EU

Gaining EU GMP certification in Czechia for distribution to European markets; and

The Board reconfirms its guidance of $65m to $75m Revenue for FY26 and $11.5m to $13.5m Underlying EBITDA, underpinned by strong Q1 results

CONTACT



JAMES EMONSON
ALPINE CAPITAL
Corporate Advisor
jemonson@alpinecapital.au